Effects of Dapagliflozin, a SGLT2 inhibitor, on Body Composition in Japanese Type 2 Diabetes Patients without severe Obesity
Not Applicable
- Conditions
- Type 2 Diabetes
- Registration Number
- JPRN-UMIN000029205
- Lead Sponsor
- Jinnouchi Hispital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
severe obesity (BMI>35) Type 1 DM ketoacidosis unstable clinical conditions active infection, liver disease, cancer eGFR<45
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain Dapagliflozin's effects on body composition in non-severely obese Japanese Type 2 Diabetes patients?
How does Dapagliflozin compare to metformin or GLP-1 agonists in improving body composition in Japanese Type 2 Diabetes patients without severe obesity?
Which biomarkers correlate with Dapagliflozin-induced changes in adipose tissue distribution in Type 2 Diabetes patients with mild obesity?
What are the potential adverse events of SGLT2 inhibitors like Dapagliflozin in Japanese populations with Type 2 Diabetes and normal BMI?
How do SGLT2 inhibitors like Dapagliflozin synergize with insulin or DPP-4 inhibitors in managing Type 2 Diabetes in non-severely obese Japanese patients?